The Think Hadrom 2025: Neuro-Oncology event focuses on the use of hadrontherapy in the treatment of brain tumors, with a particular emphasis on low-grade gliomas, glioblastomas, and meningiomas. Hadrontherapy is an advanced radiotherapy modality that exploits the physical and radiobiological advantages of particles such as protons and carbon ions. In neuro-oncology the rational for increasing the use of hadrontherapy is to: -miminize the dose to neural structures in order to reduce the risk of toxicity and neurocognitive impairment -overcome the intrinsic radioresistance of aggressive tumors such as high grade meningiomas and glioblastomas, also improving the synergistic effect of radiotherapy and innovative systemic therapies -widen the therapeutic window in challenging cases as re-irradiation The sessions will cover advances in radiotherapy, integrated therapeutic strategies, and management of complications. This event gathers national and international experts to explore multidisciplinary approaches, optimize therapeutic protocols, and improve clinical outcomes in neuro-oncology.